Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Fulcrum Therapeutics Inc shares valued at $1,831 were sold by Tourangeau Greg on May 07 ’24. At $7.76 per share, Tourangeau Greg sold 236 shares. The insider’s holdings dropped to 11,571 shares worth approximately $41539.89 following the completion of this transaction.
As published in a research note from H.C. Wainwright on September 13, 2024, Fulcrum Therapeutics Inc [FULC] has been rated down from a Buy to a Neutral and the price target has been revised to $4 from $17. Analysts at Stifel downgraded the stock from ‘”a Buy”‘ to ‘”a Hold”‘ outlook in a report released in mid September. As of September 12, 2024, RBC Capital Mkts has decreased its “an Outperform” rating to a “Sector perform” for FULC. Earlier on September 12, 2024, Leerink Partners downgraded its rating. Their new recommendation was “a Market perform” for FULC stock which previously was a “an Outperform”.
Analyzing FULC Stock Performance
During the last five days, there has been a surge of approximately 18.09%. Over the course of the year, Fulcrum Therapeutics Inc shares have dropped approximately -23.62%. Shares of the company reached a 52-week high of $5.17 on 01/06/25 and a 52-week low of $2.32 on 04/07/25. A 50-day SMA is recorded $3.19, while a 200-day SMA reached $4.77.
Support And Resistance Levels for Fulcrum Therapeutics Inc (FULC)
According to the 24-hour chart, there is a support level at 3.43, which, if violated, would cause prices to drop to 3.28. In the upper region, resistance lies at 3.81. The next price resistance is at 4.03. RSI (Relative Strength Index) is 64.13 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.59, which suggests the price will decrease in the coming days. Percent R is at 18.06%, indicating bullish price movement. Stochastics %K at selling indicates that the stock is to be held.
